dm+d

Unassigned

New Medicines

Early Alzheimer's disease (MCI and mild)

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Optimized, fully human antibody that binds and neutralises disease-relevant aggregated forms of amyloid-beta
Early Alzheimer's disease (MCI and mild)
Subcutaneous injection

Further information

Yes

Evidence based evaluations